Allakos (ALLK)

• Market cap: $29.5M
• 1 day: 0.93%
• 5 days: 1.88%
• 1 month: 28.40%
• 3 months: -61.89%
• 6 months: -49.85%
• Year to date: -73.71%
• 1 year: -69.25%
• 5 years: -99.48%
• 10 years: -98.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation. Its portfolio consists of antibodies that target receptors, particularly Siglec-6, Siglec-8 and other anti-Siglec antibodies, including some antibodies in preclinical development.

Employees: 61

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 3 (+2) [Q4]

96% more capital invested

Capital invested by funds: $45.9M [Q3] → $90M (+$44.1M) [Q4]

4.14% more ownership

Funds ownership: 79.07% [Q3] → 83.21% (+4.14%) [Q4]

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

1% less funds holding

Funds holding: 78 [Q3] → 77 (-1) [Q4]

30% less repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 27